Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available.
FDA Modernization Act 3.0
U.S. Congress · HR2821 ·
Introduced
In Committee
Reported
Floor
Passed Chamber
Enacted
Progression
Introduced (+2 more)
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up… (+3 more)
Reported by the Committee on Energy and… (+1 more)
Mr. Guthrie moved to suspend the rules… (+6 more)
2025-04-10
2026-07-21
Timing in context
Introduced (+2 more)
Referred to the Subcommittee on Health.
Subcommittee Consideration and Mark-up… (+3 more)
Reported by the Committee on Energy and… (+7 more)
Received in the Senate.
2025-01-20
2026-07-21
Primary sponsor's contributions received (same period)
Jan '25
Apr '25
Jul '25
Oct '25
Jan '26
Apr '26
Jul '26
2025-01-20
2026-07-21
Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.
What the bill says
Introduced 2025-04-10. Latest action: Received in the Senate.
Summary (plain-language)
FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.
Sponsors
- Earl L. "Buddy" Carter (primary)
- Gus M. Bilirakis
- Vern Buchanan
- Nanette Diaz Barragán
- Ken Calvert
- Judy Chu
- Dan Crenshaw
- Jason Crow
- Troy A. Carter
- Mike Carey
- Rosa L. DeLauro
- Lloyd Doggett
- Lois Frankel
- Brian K. Fitzpatrick
- Scott Fitzgerald
- Josh Gottheimer
- Daniel S. Goldman
- Diana Harshbarger
- Josh Harder
- Julie Johnson
- Raja Krishnamoorthi
- Young Kim
- Thomas H. Kean, Jr.
- Ted Lieu
- Laurel M. Lee
- Michael Lawler
- Nicholas A. Langworthy
- Nicole Malliotakis
- Jerrold Nadler
- Eleanor Holmes Norton
- Joe Neguse
- Jay Obernolte
- Mark Pocan
- Maria Elvira Salazar
- Christopher H. Smith
- Darren Soto
- Hillary J. Scholten
- Claudia Tenney
- Shri Thanedar
- David G. Valadao
- Eugene Simon Vindman
- Randy K. Weber, Sr.
Text versions
What analysts say
Committee reports
-
H. Rept. 119-706
Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Off…
CBO cost estimate from the committee report (public domain).
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2026-07-21 | Received in the Senate. |
| 2026-07-20 | Mr. Guthrie moved to suspend the rules and pass the bill. |
| 2026-07-20 | Considered under suspension of the rules. (consideration: CR H4639-4640) |
| 2026-07-20 | DEBATE - The House proceeded with forty minutes of debate on H.R. 2821. |
| 2026-07-20 | Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639) |
| 2026-07-20 | On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H4639) |
| 2026-07-20 | Motion to reconsider laid on the table Agreed to without objection. |
| 2026-06-18 | Reported by the Committee on Energy and Commerce. H. Rept. 119-706. |
| 2026-06-18 | Placed on the Union Calendar, Calendar No. 614. |
| 2026-05-21 | Committee Consideration and Mark-up Session Held |
| 2026-05-21 | Ordered to be Reported by the Yeas and Nays: 44 - 0. |
| 2026-05-13 | Subcommittee Consideration and Mark-up Session Held |
| 2026-05-13 | Forwarded by Subcommittee to Full Committee by Voice Vote. |
| 2026-04-10 | Referred to the Subcommittee on Health. |
| 2025-04-10 | Introduced in House |
| 2025-04-10 | Referred to the House Committee on Energy and Commerce. |